| Literature DB >> 22534707 |
Marijana Tadic1, Branislava Ivanovic, Nada Kostic, Dragan Simic, Danica Matic, Vera Celic.
Abstract
BACKGROUND: Metabolic syndrome (MS) is a clustering of cardiovascular risk factors responsible for the development of target organ damage. The aim of this study was to determine the effect of the increasing number of MS risk factors on left ventricular function assessed by noninvasive methods. MATERIAL/Entities:
Mesh:
Year: 2012 PMID: 22534707 PMCID: PMC3560639 DOI: 10.12659/msm.882733
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Clinical characteristics of the study population.
| Controls (n=76) | 3 factors (n=91) | 4 factors (n=65) | 5 factors (n=48) | |
|---|---|---|---|---|
| Age (years) | 52±7 | 53±9 | 52±7 | 53±8 |
|
| ||||
| Gender (female/male) | 41/35 | 49/42 | 31/34 | 28/20 |
|
| ||||
| BMI (kg/m2) | 24.8±3.9 | 25.8±3.5 | 25.5±3.7 | 26.2±3.1 |
|
| ||||
| Systolic BP (mmHg) | 129±9 | 143±10 | 145±10 | 144±9 |
|
| ||||
| Diastolic BP (mmHg) | 83±7 | 91±7c | 93±7 | 94±8c |
|
| ||||
| Fasting glucose (mmol/L) | 4.59±0.44 | 5.60±0.84d | 5.83±0.75 | 6.10±0.70d |
|
| ||||
| HbA1c (%) | 4.23±0.37 | 5.12±0.70 | 5.26±0.78 | 5.40±0.81 |
|
| ||||
| Uric acid (umol/L) | 271±46 | 405±87 | 386±73 | 420±95 |
|
| ||||
| Triglycerides (g/L) | 1.50±0.26 | 1.88±0.32 | 1.94±0.44 | 2.03±0.51 |
|
| ||||
| HDL (g/L) | 1.43±0.29 | 1.28±0.31a,d | 1.10±0.25a,f | 0.94±0.21d,f |
|
| ||||
| LDL (g/L) | 2.84±0.32 | 3.16±0.29 | 3.21±0.27 | 3.27±0.35 |
|
| ||||
| Total cholesterol (g/L) | 4.50±0.58 | 5.14±0.58 | 5.08±0.70 | 5.27±0.6 |
|
| ||||
| Waist circumference (cm): | ||||
| Women | 85±8 | 97±8 | 98±9 | 100±9 |
| Men | 96±13 | 105±10 | 107±11 | 109±10 |
|
| ||||
| Hypertension (%) | / | 64 (70)d | 47 (72)f | 45 (94)d,f |
|
| ||||
| Diabetes (%) | / | 7 (8)a,c | 13 (20)a | 10 (21)c |
3 vs. 4 MS criteria (a<0.05, b<0.01); 3 vs. 5 MS criteria (c<0.05, d<0.01); 4 vs. 5 MS criteria (e<0.05, f< 0.01).
p<0.001 for all comparisons (0 vs. 3, 0 vs. 4 and 0 vs. 5 MS criteria).
Echocardiographic parameters of left ventricular structure and function.
| Controls (n=76) | 3 factors (n=91) | 4 factors (n=65) | 5 factors (n=48) | |
|---|---|---|---|---|
| LVEDD (cm) | 4.63±0.43 | 4.65±0.47 | 4.67±0.49 | 4.71±0.50 |
| LVESD (cm) | 2.92±0.44 | 2.91±0.37 | 2.94±0.41 | 2.97±0.47 |
| LA (cm) | 3.4±0.4 | 3.7±0.5b,d | 4.0±0.6b | 4.1±0.5d |
| IVS (cm) | 0.84±0.13 | 0.89±0.14b,d | 0.98±0.15b,f | 1.06±0.15d,f |
| RWT | 0.36±0.06 | 0.38±0.07b,d | 0.42±0.09b,f | 0.45±0.08d,f |
| LVM/Ht2.7 (g/m2.7) | 38.8±7.3 | 42.2±7.9b,d | 45.5±9.5b | 47.2±8.9d |
| EF (%) | 68±7 | 69±9 | 68±7 | 67±8 |
| FS (%) | 40±7 | 41±8 | 40±7 | 39±8 |
| sseptal (m/s) | 0.081±0.021 | 0.079±0.018 | 0.076±0.017 | 0.074±0.018 |
| slateral (m/s) | 0.084±0.022 | 0.082±0.019 | 0.080±0.017 | 0.078±0.019 |
| E (m/s) | 0.82±0.17 | 0.81±0.18 | 0.80±0.19 | 0.81±0.17 |
| A (m/s) | 0.60±0.15 | 1.01±0.18d | 1.05±0.21f | 1.23±0.19d,f |
| E/A | 1.34±0.24 | 0.82±0.25d | 0.79±0.24f | 0.67±0.14d,f |
| DT (ms) | 192±33 | 216±33b,d | 230±40b,e | 246±45d,e |
| e′septal (m/s) | 0.11±0.02 | 0.10±0.02b,d | 0.08±0.01b,f | 0.07±0.01d,f |
| e′lateral (m/s) | 0.13±0.02 | 0.11±0.02b,d | 0.09±0.01b,f | 0.08±0.01d,f |
| E/e′septal | 7.32±1.9 | 8.21±1.73b,d | 9.61±2.26b,f | 11.80±2.71d,f |
| E/e′lateral | 6.56±1.7 | 7.52±1.86b,d | 8.64±2.05b,f | 10.10±2.12d,f |
| E/e′average | 6.87±1.82 | 7.76±1.81a,d | 9.44±2.35a,f | 10.82±2.56d,f |
| IVRT (ms) | 79±16 | 89±13a,d | 95±19a,f | 108±24d,f |
| IVCT (ms) | 32±4 | 49±4b,d | 53±6b,f | 58±9d,f |
| ET (ms) | 326±28 | 313±22d | 308±20 | 302±16d |
| Tei index | 0.35±0.04 | 0.43±0.11b,d | 0.48±0.10b,f | 0.54±0.12d,f |
3 vs. 4 MS criteria (a<0.05, b<0.01); 3 vs. 5 MS criteria (c<0.05, d<0.01); 4 vs. 5 MS criteria (e<0.05, f< 0.01).
p<0.001 for all comparisons (0 vs. 3, 0 vs. 4 and 0 vs. 5 MS criteria);
p<0.05 for comparison 0 vs. 3 MS criteria and p<0.01 for comparisons 0 vs. 4 and 0 vs. 5 MS criteria.
Prevalence of left ventricular hypertrophy and abnormal diastolic function in the study population.
| Controls (n=76) | 3 factors (n=91) | 4 factors (n=65) | 5 factors (n=48) | p (trend) | |
|---|---|---|---|---|---|
| LV hypertrophy (%) | 4 (5) | 17 (19)e | 13 (20) | 17 (35)e | <0.001 |
| Abnormal diastolic function (%) | 7 (9) | 22 (24)c | 17 (26)e | 22 (46)c,e | <0.001 |
3 vs. 4 MS criteria (a<0.05, b<0.01); 3 vs. 5 MS criteria (c<0.05, d<0.01); 4 vs. 5 MS criteria (e<0.05, f< 0.01).
p<0.001 for all comparisons (0 vs. 3, 0 vs. 4 and 0 vs. 5 MS criteria).
Multiple variable linear regression model of RWT, E/A ratio and DT for each component of the metabolic syndrome in metabolic syndrome group.
| RWT | E/A ratio | DT (ms) | ||||
|---|---|---|---|---|---|---|
| β | p | β | p | β | p | |
| Systolic BP (mmHg) | 0.298 | <0.001 | −0.334 | <0.001 | 0.278 | <0.001 |
| Diastolic BP (mmHg) | 0.257 | <0.001 | −0.249 | 0.015 | 0.147 | 0.036 |
| Fasting glucose (mmol/l) | 0.156 | 0.068 | −0.291 | 0.001 | 0.115 | 0.092 |
| Triglycerides (mmol/l) | 0.075 | 0.224 | −0.082 | 0.102 | 0.087 | 0.152 |
| HDL (mmol/l) | −0.055 | 0.367 | 0.041 | 0.231 | 0.048 | 0.379 |
| Waist circumference (cm) | 0.193 | 0.005 | −0.182 | 0.025 | 0.125 | 0.043 |
| Model r2 | 0.76 | 0.66 | 0.72 | |||
BP – blood pressure; HDL – high density lipoprotein.
Multiple variable linear regression models of E/e′septal, E/e′lateral and E/e′average for each component of the metabolic syndrome in metabolic syndrome group.
| E/e′septal | E/e′lateral | |||
|---|---|---|---|---|
| β | p | β | p | |
| Systolic BP (mmHg) | 0.383 | <0.001 | 0.307 | <0.001 |
| Diastolic BP (mmHg) | 0.116 | 0.076 | 0.082 | 0.086 |
| Fasting glucose (mmol/l) | 0.077 | 0.179 | 0.058 | 0.221 |
| Triglycerides (mmol/l) | 0.202 | 0.001 | 0.163 | 0.044 |
| HDL (mmol/l) | −0.041 | 0.311 | −0.031 | 0.357 |
| Waist circumference (cm) | 0.266 | <0.001 | 0.241 | 0.022 |
| Model r2 | 0.68 | 0.71 | ||
BP – blood pressure; HDL – high density lipoprotein.